The tyrosine kinase inhibitor famitinib was associated with a significant improvement in progression-free survival among patients with advanced or metastatic colorectal cancer, according to the results […]

Patients with hepatocellular carcinoma (HCC) may derive greater benefit from treatment with second-line ramucirumab if their baseline alpha-fetoprotein (AFP) levels are greater than 400 ng/mL, according […]

Patients with rectal cancer who completed neoadjuvant therapy with a clinical complete response but did not undergo rectal resection had similar 4-year survival rates as patients […]

Newly diagnosed metastatic colorectal cancer patients with higher vitamin D levels had better outcomes after treatment with a combination of chemotherapy and targeted therapy. The results […]

The addition of the novel agent MM-398 to second-line 5-FU/leucovorin extended survival in patients with metastatic pancreatic cancer, according to an expanded analysis of the phase […]

Twice as many patients with metastatic colorectal cancer remained alive after 5 years with a four-drug chemotherapy regimen plus bevacizumab (Avastin) versus three drugs and the […]

The 2015 ASCO Gastrointestinal Cancers Symposium, held last month in San Francisco, brought together oncology professionals to highlight the latest research and science in cancers of […]

SAR650984 (SAR) is another anti-CD38 antibody that has shown single-agent activity in Phase I testing among heavily pre-treated myeloma patients. In this Phase Ib trial, researchers […]

The recently approved targeted treatment carfilzomib has been shown to help slow or halt the spread of cancer by targeting the mechanisms that control excess proteins […]

The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous […]

New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented at […]

Novel treatments that harness the body’s own immune cells to attack cancer cells demonstrate safe and durable responses in patients with relapsed and treatment-resistant blood cancers, […]